Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2044797#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A2".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 2044797.bibtex.
- aggregation hasFormat 2044797.csv.
- aggregation hasFormat 2044797.dc.
- aggregation hasFormat 2044797.didl.
- aggregation hasFormat 2044797.doc.
- aggregation hasFormat 2044797.json.
- aggregation hasFormat 2044797.mets.
- aggregation hasFormat 2044797.mods.
- aggregation hasFormat 2044797.rdf.
- aggregation hasFormat 2044797.ris.
- aggregation hasFormat 2044797.txt.
- aggregation hasFormat 2044797.xls.
- aggregation hasFormat 2044797.yaml.
- aggregation isPartOf urn:issn:1753-4658.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study".
- aggregation abstract "Rationale: Previous studies have demonstrated that long-term low-dose macrolides are efficacious in cystic fibrosis (CF) and diffuse panbronchiolitis, two chronic neutrophilic airway diseases. Aims: The aims of this study were to evaluate the efficacy and safety of low-dose neomacrolides as add-on therapy in patients with severe asthma and/or bronchiectasis and to identify predictors for therapeutic response. Methods: In a retrospective observational cohort study, we examined 131 adult, non-CF patients with severe asthma and/or bronchiectasis, receiving low-dose neomacrolides as add-on treatment. Pulmonary function tests and symptom scores were assessed at baseline and after 3 to 8 weeks of therapy. Results: After 3-8 weeks of treatment with low-dose neomacrolides, 108 patients were available for evaluation. In asthma patients (n¼47), pulmonary function tests and symptom scores improved significantly. Responders (>=7% forced expiratory volume in one second predicted [FEV1%] improvement) were older (55 vs. 47 years; p¼0.042) and had a longer duration of asthma (29 vs. 9 years; p¼0.052). In patients with bronchiectasis only (n¼61), symptom scores improved significantly. Responders (>=60% symptom score improvement) were older (61 vs. 53 years; p¼0.004), more frequently male (53% vs. 27%; p¼0.043), and there was a nonsignificant trend towards higher high-resolution CT (HRCT) score for bronchiectasis in responders (6.4 vs. 4.6; p¼0.053). In multivariate logistic regression analysis, age and male gender were independent predictors for improvement in this group. Conclusion: The results of this retrospective study suggest that neomacrolides may be useful as an add-on therapy in patients with severe asthma and/or bronchiectasis. Older age may predict good response in patients with severe asthma, whereas older age, male gender and a higher HRCT score for bronchiectasis may predict therapeutic response in patients with bronchiectasis only. Prospective controlled trials of neomacrolides in patients with severe asthma are needed to confirm these observations.".
- aggregation authorList BK934886.
- aggregation endPage "386".
- aggregation issue "6".
- aggregation startPage "377".
- aggregation volume "5".
- aggregation aggregates 2044812.
- aggregation isDescribedBy 2044797.
- aggregation similarTo 1753465811406771.
- aggregation similarTo LU-2044797.